CVSI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 22:58):

Stats
Dzisiejszy wolumen	241 919
Średni wolumen	276 861
Kapitalizacja rynkowa	7.18M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.20
ATR14	$0.00200 (4.55%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-15	Dowling Joseph D	Buy	2 500 000	Employee Stock Option (right to buy)
2023-03-15	Grasser Joerg	Buy	1 250 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	500 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	0
2022-10-21	Mccorkle William	Buy	0

INSIDER POWER
100.00
Last 97 transactions
Buy: 17 580 526 \| Sell: 13 733 278

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: 0.25 (neutral)

Signal:(54.779) Neutral

CV Sciences, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CV Sciences, Inc. Korelacja - Waluta/Towar

0.57
( weak )

0.00
( neutral )

-0.42
( neutral )

CV Sciences, Inc. Finanse

Annual	2023
Przychody:	$16.00M
Zysk brutto:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2023
Przychody:	$16.00M
Zysk brutto:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2022
Przychody:	$16.21M
Zysk brutto:	$5.55M (34.25 %)
EPS:	$-0.0595

FY	2021
Przychody:	$20.05M
Zysk brutto:	$8.62M (42.98 %)
EPS:	$-0.140

Financial Reports:

No articles found.

CV Sciences, Inc.

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.